Feature

Newly approved tirzepatide’s retail price announced


 

Tirzepatide (Mounjaro) – the new twincretin approved by the Food and Drug Administration for glycemic control in patients with type 2 diabetes – was priced by Lilly, the company that will market the drug, at a list price of $974.33 for four weekly doses regardless of dose size, a cost that adds up to about $12,666 per year, according to a statement made on May 20 by a Lilly spokesperson.

This price puts tirzepatide, which combines the activity of two of the primary human incretins in one molecule, roughly in the same ballpark as what might be its main competitor, semaglutide (Ozempic) for type 2 diabetes, which retails at many U.S. pharmacies for about $925 for four weekly doses, or about $12,025 per year, although Ozempic’s posted retail price is about $100 higher for four doses.

According to the Lilly spokesperson, discount programs could reduce the monthly out-of-pocket cost for patients to as little as $25.

Tirzepatide, which received approval from the FDA on May 13, is a dual glucagonlike peptide–1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide agonist. Several GLP-1 receptor agonists are already approved in the United States, including semaglutide, which is indicated as Wegovy for weight loss in patients with obesity regardless of diabetes status.

A version of this article first appeared on Medscape.com.

Recommended Reading

Tirzepatide succeeds in obesity in SURMOUNT-1, says Lilly
Clinician Reviews
New research holds promise for fighting obesity, says expert
Clinician Reviews
Topline results for dapagliflozin in HFpEF: DELIVER
Clinician Reviews
Calorie counting and exercise ‘of limited value’ for obesity weight loss
Clinician Reviews
Vegan diet helps shed pounds but doesn’t dint diabetes
Clinician Reviews
Screening for diabetes at normal BMIs could cut racial disparities
Clinician Reviews
Grit your teeth for a lesser-known complication of diabetes
Clinician Reviews
Could new therapy for food ‘cues’ improve weight loss?
Clinician Reviews
Pancreatic involvement in COVID-19: What do we know?
Clinician Reviews
Does COVID-19 raise the risk for diabetes?
Clinician Reviews